Physician
Pulmonology
Dr. Chand Khanna, MD
|
|
Give Review
Dr. Chand Khanna works in the field of Pulmonology. He went to Government Medical College Amritsar. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Chand Khanna is a published doctor and has 102 publications published. The lastest was: 'Effects of long-term thyroid hormone suppressive treatment on the cardiac functions.' He accepts Medicare.
Publications
- A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation.
- p53 Loss Increases the Osteogenic Differentiation of Bmscs.
- The Role of Clinical Trials in Veterinary Oncology.
- Imputation and subset based association analysis across different Cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.
- Tumor microenvironment-based feed-forward regulation of NOS2 in breast Cancer progression.
- Mitochondrial retrograde signaling induces epithelial-mesenchymal transition and generates breast Cancer stem cells.
- Genome-wide association study identifies two susceptibility loci for osteosarcoma.
- Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
- Role of ezrin in osteosarcoma metastasis.
- Prospective Molecular Profiling of Canine Cancers Provides a Clinically Relevant Comparative Model for Evaluating Personalized Medicine (PMed) Trials.
- A novel noninvasive method for evaluating experimental Lung metastasis in mice.
- Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma.
- Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray.
- A compendium of canine normal tissue gene expression.
- Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening.
- Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
- More on cultivating veterinarian-scientists.
- Modeling opportunities in comparative oncology for drug development.
- Modeling metastasis biology and therapy in real time in the mouse Lung.
- Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.
- Bridging the gap between experimental animals and humans in osteosarcoma.
- Osteosarcoma.
- Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis.
- Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.
- The Comparative Oncology Trials Consortium: using spontaneously occurring Cancers in dogs to inform the Cancer drug development pathway.
- Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
- Guiding the optimal translation of new Cancer treatments from canine to human Cancer patients.
- Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.
- Catching Cancer by the tail: new perspectives on the use of kinase inhibitors.
- Revisiting the seed and soil in Cancer metastasis.
- Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to Cancer vasculature.
- Inhibition of tumor cell motility by the interferon-inducible GTPase MxA.
- Murine osteosarcoma primary tumour growth and Metastatic progression is maintained after marked suppression of serum insulin-like growth factor I.
- Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs.
- Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma.
- Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting an...
- Novel targets with potential therapeutic applications in osteosarcoma.
- Inhibition of Metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.
- Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility.
- Translation of new Cancer treatments from pet dogs to humans.
- Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.
- Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine Pulmonary metastases.
- The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation.
- Immune synapse formation requires ZAP-70 recruitment by ezrin and CD43 removal by moesin.
- Fas-negative osteosarcoma tumor cells are selected during metastasis to the Lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.
- Comparative oncology today.
- Preclinical studies of treosulfan demonstrate potent activity in Ewing''s sarcoma.
- Corruption of the Fas pathway delays the Pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemci...
- Fishing for the origins of Cancer.
- Expression of the cytoskeleton linker protein ezrin in human Cancers.
- Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis.
- Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
- Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring Cancers.
- Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma.
- Immune reconstitution prevents Metastatic recurrence of murine osteosarcoma.
- Ezrin mediates growth and survival in Ewing''s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway.
- The dog as a Cancer model.
- Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma.
- The molecular biology of Pulmonary metastasis.
- CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling.
- CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcriptio...
- Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas.
- Molecular approaches in pediatric oncology.
- The biology of metastases in pediatric sarcomas.
- Rapamycin inhibits ezrin-mediated Metastatic behavior in a murine model of osteosarcoma.
- Modeling metastasis in vivo.
- The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis.
- Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key Metastatic regulators.
- Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
- Tumor expression of 4-1BB ligand sustains tumor lytic T cells.
- Targeting the Lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers.
- MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
- STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicent...
- A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluat...
- Biologically relevant orthotopic neuroblastoma xenograft models: Primary adrenal tumor growth and spontaneous distant metastasis.
- Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays.
- Early development of transient hypothyroidism after I131 therapy for thyrotoxicosis.
- Prognostic significance of thyroid antibodies in hyperthyroid patients treated with antithyroid drugs.
- Efficacy of standard ten millicurie dose of radio-iodine in management of autonomously functioning toxic thyroid Nodules.
- Investigations of thyroid Diseases--an update on diagnostic methods.
- Prognostic role of stress thallium test in patients with significant coronary artery Disease.
- Evaluation of long-term results of two schedules of treatment for toxic multinodular goitre with radioiodine therapy (I 131).
- Predictor of outcome of hyperthyroidism due to Graves Disease: serum triiodothyronine/thyroxine ratio.
- Role of radionuclide perfusion study in cold solitary thyroid Nodule for diagnosis of malignancy: a complimentary diagnostic modality to fine needle aspiration cytology.
- Response to exercise and ambulatory blood pressure monitoring in essential Hypertension.
- Solitary nodular goiter. Review of cytomorphologic features in 441 cases.
- Clinical, biochemical and cytomorphological observations in juvenile Chronic lymphocytic thyroiditis.
- Effects of long-term thyroid hormone suppressive treatment on the cardiac functions.
- Blood mercury in workers exposed to the preparation of mercury cadmium telluride layers on cadmium telluride base.
- Long-term results of two schedules of treatment for toxic multinodular goitre with radioiodine therapy.
- Technetium-99m dextran: a promising new protein-losing enteropathy imaging agent.
- Diagnosing protein losing enteropathy. A new approach using Tc-99m human immunoglobulin.
- Effect of some chemical radioprotectors on mouse bone marrow.
- Evaluation of the healing process in fractures using early and delayed bone scanning.
- Thyrotoxicosis--treatment by I131 therapy and early prediction of hypothyroidism following this therapy.
- Efficacy of hepatobiliary scintigraphy in demonstrating cholangio-colic fistulae. Is formation of internal biliary fistula related to external leak closure?
- Heat hyper-pyrexia and jaundice.
- ''U'' wave in health and Disease.
- 131I therapy of hyperthyroidism: a five-year follow up.
- Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.
- A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.
Procedures Preformed
- Bronchoscopy
- Thoracentesis
- Ventilation Management
Conditions Treated
- Acidosis
- Alkalosis
- Asthma
- Atelectasis
- View All
Doctors Specialties
- Pulmonology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Medicaid
- Blue Card PPO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California HMO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Access Plus Savenet
- Basic Exclusive PPO for Small Business
- Basic PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Covered California - Bronze PPO
- Health Net PPO
- Individual and Family PPO
- Kaiser Permanente
- LACare
- Medicare MCR
- National Elevator
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- USI Affinity
- Worker's Compensation WC
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Maimonides Medical Center -
University of Colorado -
Government Medical College Amritsar
Drug Facts
| NPI NUMBER | 1699776302 | |
| NPPES Provider LastName | KHANNA | |
| NPPES Provider FirstName | CHAND | |
| NPPES Provider ZIPCode | 913212409 | |
| NPPES Provider State | CA | |
| Specialty Description | Pulmonary Disease | |
| Total Claim Count | 2134.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 35.0 | |
| Percent Opioid Claims | 1.64 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699776302 |
| Last Name Of The Provider | KHANNA |
| First Name Of The Provider | CHAND |
| View All |
Similar Doctors
|
|
Dr. Charanjit L. Saroa, MD
 This Doctor is OpenDoctor Recommended.
|